The effect of imatinib on mortality from chronic myelogenous leukemia (CML) has not been assessed even though there have been a lot of reports regarding the improvement it has caused on survival outcomes of CML patients. A reduction in mortality is not implied just due to a survival benefit in clinical trials. The researchers collected